Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: November 30, 2018
Event: Entry into a new Five Year Credit Agreement and termination of the prior credit facility.
Key Financial Metrics
This filing reports on a financing arrangement rather than operational performance. Consequently, revenue, profit, cash flow, margins, and liquidity metrics are not disclosed in this document.
- New Credit Facility: $5 billion unsecured revolving credit agreement.
- Outstanding Borrowings (New): $0 as of November 30, 2018.
- Maturity Date (New): November 30, 2023 (5 years from effective date).
- Interest Rate Basis: Base rate or Eurodollar rate plus an applicable margin based on credit ratings.
Material Changes Versus Prior Period
Abbott terminated its previous Five Year Credit Agreement dated July 10, 2014, which also provided up to $5 billion in unsecured borrowing capacity. The prior agreement was set to mature on July 10, 2019. There were no outstanding borrowings under the terminated agreement at the time of termination. The new agreement extends the maturity timeline by approximately 4.5 years compared to the original expiration of the prior facility.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the establishment of a new credit facility to replace the expiring one, maintaining the same borrowing capacity of $5 billion. The full text of the agreement will be filed in the annual report on Form 10-K for the period ending December 31, 2018.
Risks and Contingencies: The agreement includes customary representations, warranties, affirmative and negative covenants, and events of default for unsecured financings. Interest costs will fluctuate based on Abbott's credit ratings.
Important Facts for Investor Verification
- Verify the specific interest rate margins and fee structures in the full Revolving Credit Agreement text (to be filed in the 2018 Form 10-K).
- Confirm that no borrowings were drawn under the new facility as of the filing date.
- Monitor future credit rating changes, as they directly impact the cost of borrowing under this agreement.
- Note that the filing does not contain operational financial results (revenue, earnings, cash flow) for the period.